Clinically researched botanical ingredient offers three-in-one benefit support for metabolic health.
Givaudan today announced the launch of Novaberin™, a patent-pending botanical ingredient designed to support metabolic health. Metabolic health refers to how effectively our bodies regulate energy, process nutrients and maintain homeostasis. In a six-month clinical study on Novaberin™ involving adults seeking support for healthy metabolic function[1], key outcomes included support for healthy weight management and retaining healthy blood glucose and lipid levels.2 Formulated from Barberry (Berberis aristata), a natural of source berberine, and Amla fruit (Phyllanthus emblica), Novaberin™ delivers a multi-benefit approach in a convenient daily dose of 2 x 250 mg.
As the longevity market evolves, consumers are increasingly viewing metabolic health as a foundation for lifelong wellbeing. Today, 40% are actively using products to support cardiovascular health, metabolic health and weight management.3 “Consumers are increasingly looking for solutions that go beyond weight management alone and support broader metabolic health goals,” said Timothée Olagne, Head of Marketing, Health & Functional Business Unit. “Novaberin™ offers a clinically researched botanical that mirrors the convenience consumers increasingly expect, while supporting three areas of metabolic health.”
Novaberin™ begins with responsibly sourced botanicals from India. The ingredient comes with full traceability and identity documentation to support authenticity and quality assurance. Its carefully monitored origins help build trust in a growing market that is increasingly affected by adulteration concerns.
Suitable for capsules and tablets and available to customers in the US, Novaberin™ is the latest addition to Givaudan’s growing portfolio of science-backed metabolic health solutions.
Supply Side Global visitors to booth 3264 will be able to connect with Givaudan experts to learn more about these ingredients and how they play into the growing longevity market. More information can be found at https://healthnutritionhub.givaudan.com/ingredients/novaberin
1 Publication pending. Novaberin 250 mg twice daily (n=17) vs placebo (n=16); mean change from baseline at day 180, all p<0.05 vs placebo
2 Data on file.
3 NBJ Healthy Aging Report 2026
